English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Charles River Acquires Wuxi Pharma for $1.6 billion

Apr. 25, 2010

Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, announced on April 26, 2010 that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.
According to Charles River’s statement, this deal will create the first global contract research organization (“CRO”) offering fully integrated early-stage drug development services to clients globally.